Published in J Immunol Methods on March 25, 1983
Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med (1998) 2.07
Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood. Immunology (1989) 0.87
Immunological surveillance against DNA-virus-transformed cells: correlations between natural killer cell cytolytic competence and tumor susceptibility of athymic rodents. J Virol (1987) 0.85
The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. Immunology (1990) 0.83
Predictive margins with survey data. Biometrics (1999) 9.18
Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity (1995) 7.08
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Asthma and air pollution in the Los Angeles area. Am J Public Health (1980) 4.02
The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity (1995) 3.99
Methods for analyzing panel studies of acute health effects of air pollution. Biometrics (1979) 2.76
Modelling the sampling design in the analysis of health surveys. Stat Methods Med Res (1996) 2.74
Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med (1998) 2.07
The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Engl J Med (1995) 1.74
Survey inference for subpopulations. Am J Epidemiol (1996) 1.69
Choice of column scores for testing independence in ordered 2 X K contingency tables. Biometrics (1987) 1.59
Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol (1997) 1.56
Selecting drug combinations based on total equivalent dose (dose intensity) J Natl Cancer Inst (1990) 1.56
Data monitoring committees and interim monitoring guidelines. Control Clin Trials (1999) 1.55
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol (2000) 1.53
Life events, depressive symptoms, and immune function. Am J Psychiatry (1987) 1.42
Analyzing health surveys for cancer-related objectives. J Natl Cancer Inst (1999) 1.42
Fractalkine-mediated endothelial cell injury by NK cells. J Immunol (2000) 1.34
Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst (1992) 1.28
Censoring distributions as a measure of follow-up in survival analysis. Stat Med (1986) 1.21
Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol (1998) 1.20
Apical root resorption in orthodontically treated adults. Am J Orthod Dentofacial Orthop (1996) 1.19
Effective sample sizes for confidence intervals for survival probabilities. Stat Med (1987) 1.15
Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 1.15
Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst (1987) 1.10
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 1.09
Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture. Cancer Res (1972) 1.09
Human peripheral blood CD4+ and CD8+ T cells express Th1-like cytokine mRNA and proteins following in vitro stimulation with heat-inactivated Brucella abortus. Infect Immun (1995) 1.07
Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol (2001) 1.06
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer (1984) 1.04
Quantitative analysis of the orthodontic and orthopedic effects of maxillary traction. Am J Orthod (1983) 1.02
Immunological changes in young and old adults during brief laboratory stress. Psychosom Med (1991) 0.99
IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol (1995) 0.99
Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells. J Immunol (1993) 0.97
Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha. J Immunol (1996) 0.96
Transcription, processing, and turnover of RNA from the Drosophila mobile genetic element copia. Dev Biol (1982) 0.94
Antigen-induced changes in the proportion of antigen-binding cells expressing IgM, IgG, and IgD receptors. J Immunol (1979) 0.94
Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res (1987) 0.93
Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway. J Immunol (1999) 0.92
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst (1992) 0.92
Building quality of life assessment into cancer treatment studies. Oncology (Williston Park) (1992) 0.92
Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood (1999) 0.90
Quantitative detection of cytotoxic antibodies against tumor-specific antigens of murine sarcomas induced by 3-methylcholanthrene. J Natl Cancer Inst (1970) 0.89
Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood (1996) 0.89
Analysis of the clinical utility of a predictive chemosensitivity assay. Stat Med (1986) 0.89
Cell-mediated cytotoxicity against human bladder cancer. Int J Cancer (1974) 0.88
Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events. Blood (1996) 0.88
Partitioning the components of maxillary tooth displacement by the comparison of data from three cephalometric superimpositions. Angle Orthod (1996) 0.87
Assessment of alloreactive T cell subpopulations of aged mice in vivo. CD4+ but not CD8+ T cell-mediated rejection response declines with advanced age. Eur J Immunol (1994) 0.87
Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst (1992) 0.86
Monocyte-mediated augmentation of human natural cell-mediated cytotoxicity. Cell Immunol (1985) 0.86
Clinical xenotransplantation. JAMA (2001) 0.86
Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics. J Immunol (1986) 0.85
Immunological responses of aging Japanese A-bomb survivors. Radiat Res (1988) 0.84
Regression analysis with clustered data. Stat Med (1994) 0.84
The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes. Immunology (1990) 0.83
Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha. J Immunol (1999) 0.83
Co-stimulation of T cells with CD2 augments TCR-CD3-mediated activation of protein tyrosine kinase p72syk, resulting in increased tyrosine phosphorylation of adapter proteins, Shc and Cbl. Int Immunol (1998) 0.83
Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer (1993) 0.83
Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin Exp Immunol (1983) 0.83
Control of cell cycle progression in human natural killer cells through redox regulation of expression and phosphorylation of retinoblastoma gene product protein. Blood (1997) 0.82
Mandibular remodeling measured on cephalograms. 1. Osseous changes relative to superimposition on metallic implants. Am J Orthod Dentofacial Orthop (1992) 0.82
Involvement of protein tyrosine kinase p72syk and phosphatidylinositol 3-kinase in CD2-mediated granular exocytosis in the natural killer cell line, NK3.3. J Immunol (1997) 0.81
Increased binding of IL-2 and increased IL-2 receptor mRNA synthesis are expressed by an NK-like cell line in response to IL-1. J Immunol (1988) 0.81
In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning (1988) 0.81
The decision to extract: part II. Analysis of clinicians' stated reasons for extraction. Am J Orthod Dentofacial Orthop (1996) 0.81
Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci (1998) 0.80
Suppression of murine natural killer cell activity by adherent cells from aging mice. Mech Ageing Dev (1985) 0.80
Projection from previous studies. A caution. Control Clin Trials (1990) 0.80
Lymphokine-activated killer cells derived from murine bone marrow: age-associated difference in precursor cell populations demonstrated by response to interferon. Cell Immunol (1988) 0.80
Microcytotoxicity tests on human cells in culture: effect of contamination with mycoplasma. Proc Soc Exp Biol Med (1973) 0.80
Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody. Cancer (1984) 0.79
Testing chemotherapeutic combinations in the Human Tumor Colony--Forming Assay. J Surg Oncol (1988) 0.79
The effect of exercise on natural killer cell activity in young and old subjects. J Gerontol (1989) 0.78
Increased susceptibility of old mice to plasmacytoma induction. J Gerontol (1986) 0.78
Rapid kinetics of lysis in human natural cell-mediated cytotoxicity: some implications. Cell Immunol (1983) 0.78
Superimpositional assessment of treatment-associated changes in the temporomandibular joint and the mandibular symphysis. Am J Orthod (1983) 0.78
Mechanisms of tumor-specific enhancement versus resistance toward a methylcholanthrene-induced murine sarcoma. Transplantation (1970) 0.78
Prediction of mandibular rotation: an empirical test of clinician performance. Am J Orthod (1984) 0.78
The decision to extract: Part 1--Interclinician agreement. Am J Orthod Dentofacial Orthop (1996) 0.78
Assessment of a method for the prediction of mandibular rotation. Am J Orthod Dentofacial Orthop (1987) 0.78
Redox-sensitive events in Fas-induced apoptosis in human NK cells include ceramide generation and protein tyrosine dephosphorylation. Int Immunol (1998) 0.78
Assessing causal relationships between treatments and clinical outcomes: always read the fine print. Bone Marrow Transplant (2011) 0.78
Subsidence of the femoral prosthesis. A stereophotogrammetric evaluation. Clin Orthop Relat Res (1985) 0.78
Lower molar and incisor displacement associated with mandibular remodeling. Angle Orthod (1997) 0.77
Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell. Mech Ageing Dev (1987) 0.77
Life events, depression, and natural killer cell activity. Psychopharmacol Bull (1986) 0.77
Signal transduction via phosphorylated adhesion molecule, LFA-1 beta (CD18), is increased by culture of natural killer cells with IL-2 in the generation of lymphokine-activated killer cells. Int Immunol (1993) 0.76
Endogenous opioids and the exercise-induced augmentation of natural killer cell activity. J Lab Clin Med (1988) 0.76
Tumor-specific active enhancement of a murine sarcoma. Tissue Antigens (1971) 0.76
Effect of redox modulation on xenogeneic target cells: the combination of nitric oxide and thiol deprivation protects porcine endothelial cells from lysis by IL-2-activated human NK cells. J Immunol (2001) 0.75
The limited precision of phase I trials. J Natl Cancer Inst (1994) 0.75
Phase II trials of small-cell lung cancer. J Clin Oncol (1992) 0.75
Inter-rater agreement among orthodontists in a blocked experiment. Stat Med (1985) 0.75
Estimating the utility of matching in case-control studies. J Chronic Dis (1984) 0.75
Kendall's tau with a blocking variable. Biometrics (1984) 0.75
The use of three baseline values in intervention studies: application to evaluation of immune modulation therapies. Immunobiology (1984) 0.75
Quantitation of maxillary remodeling. 2. Masking of remodeling effects when an "anatomical" method of superimposition is used in the absence of metallic implants. Am J Orthod Dentofacial Orthop (1987) 0.75